AzTrials
AzTrials

SciaticaPhase 4NCT00749996

Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

A Phase 4 study testing DIAM™ Spinal Stabilization System and Herniectomy in people with Sciatica and Back Pain, run by Medtronic Spinal and Biologics at 19 sites in 8 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study aims at assessing the short and long-term effectiveness and patient perception of benefit with the use of a DIAM™ Spinal Stabilization System in the treatment of complex disc disease at a single level from L2 to L5. Read more about this study

Who is it for?
Ages 20 to 60 years
Conditions the study is for
Sciatica, Back Pain
What is being tested?
DIAM™ Spinal Stabilization System and Herniectomy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
165 participants
Where
19 sitesin 8 countries
Study dates
Nov 2006to Jun 2013
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Has a history of sciatica (radicular pain) for at least 6 weeks, but not more than 1 year secondary to one symptomatic lumbar disc herniation at the levels L2-L5 as confirmed by patient history and clinical evaluation, and without major neurological impairment (i.e. not less than M 3/5; Medical Research Council Classification);
  • Has a history of continuous low back pain for no more than 1 year secondary to lumbar degenerative disc disease (intermittent back pain may occur for more than a year);
  • Has pre-treatment back pain score greater than or equal to 3, concomitant with leg pain score greater than or equal to 6. Leg pain score must be greater than back pain score (pain intensity score measured on a 10 cm VAS scale);
  • Has one symptomatic disc herniation: protrusion, extrusion or sequestration (Milette \& Fardon, 2001) as confirmed by MRI at the target level;
  • Evidence of disc degeneration ≤ Grade IV at the target and adjacent levels as confirmed by MRI (Pfirrmann, 2001);
  • Has an Oswestry Disability Index (ODI) score ≥ 34%;
Show all 9Show fewer
  • Has been treated non-operatively (e.g. bed rest, physical therapy, medications, TENS, manipulation, hydrotherapy, acupressure/acupuncture, massage, bracing and/or spinal injections) for at least 6 continuous weeks unless strong clinical grounds for expediting surgery;
  • Patient male or female, age 20-60 years inclusive and is skeletally mature;
  • Is willing and able to comply with the study plan and able to provide an informed consent;

Who cannot join

  • Has a primary diagnosis of spinal disorder other than degenerative disc at the involved level;
  • Has a symptomatic disc herniation at more than one lumbar level;
  • Requires a herniectomy at more than one lumbar level;
  • Has a disc degeneration at the treated and adjacent levels > Grade IV (Pfirrmann, 2001);
  • Has a decrease of disc height ≥ 30% as measured by the center of the disc space, and compared to the disc space at the next superior spinal level;
  • Has Modic changes on MRI greater than Grade I at the target level;
Show all 21Show fewer
  • Has Modic changes on MRI at the adjacent levels;
  • Has an advanced degree of retrolisthesis as shown by lateral X-rays (> 25%, i.e. grade I as per Meyerding);
  • Has a clinical evidence of lysis, antero listhesis or scoliosis (Cobb angle more than 10°);
  • Has signs of segmental instability: more than 4 mm of translation or more than 10° angular motion between adjacent end plates (comparing flexion and extension views);
  • Has congenital or iatrogenic posterior element insufficiency (e.g. facet resection, spondylolysis, pars fracture, or Spinal Bifida Occulta);
  • Has had any previous lumbar spine surgery;
  • Has a Waddell signs of inorganic behaviour score greater than or equal to 3;
  • Has evidence of an active disruptive psychiatric disorder, cognitive impairment or other known condition, significant enough to impact the perception of pain, precludes surgical procedure, clinical evaluation and/or ability to evaluate treatment outcome as determined by investigator;
  • Has a known allergy to silicone, polyethylene, or titanium;
  • Is an alcohol and /or drug abuser, as defined by currently undergoing treatment for alcohol and/or drug abuse;
  • Has obesity defined by BMI greater than or equal to 35;
  • Inability to complete the questionnaires;
  • Planned pregnancy during the course of the study;
  • Previous enrollment into a spine study;
  • Vulnerable patients or unable to exercise free informed consent;

Trial locations and contacts

19 sites in 8 countries.

19 sites in 8 countries

Belgium4 sites
  • Cliniques Universitaires Bruxelles Hôpital Erasme

    Brussels

  • AZ Sint-Lucas

    Ghent

  • Hôpital de la Citadelle

    Liège

  • AZ Sint-Elisabeth Hospital

    Zottegem

Other trials in Belgium

Germany3 sites
  • Otto-Von-Guericke Universität

    Magdeburg

  • CA NCH Klinikum rechts der Isar/München

    München

  • Medizinisches Zentrum Kreis Aachen

    Würselen

Other trials in Germany

Switzerland3 sites
  • Hôpital Fribourgeois

    Fribourg

  • Hôpitaux Universitaires de Genève

    Geneva

  • Hirslanden Klinik St. Anna

    Lucerne

Other trials in Switzerland

United Kingdom3 sites
  • Chase Farm Hospital

    Enfield

  • St. Georges Hospital

    London

  • Greater Manchester Neuroscience Center

    Salford

Other trials in United Kingdom

Italy2 sites
  • Anthea Casa di Cura

    Bari

  • Istituto Ortopedico Galeazzi

    Milan

Other trials in Italy

Spain2 sites
  • Hospital Universitari Bellvitge

    Barcelona

  • Hospital de León

    León

Other trials in Spain

Czechia1 site
  • University Hospital Olomouc, dept of Neurosurgery

    Olomouc

Other trials in Czechia

Poland1 site
  • St. Luke Hospital, University of Rzeszow, dept of Neurosurgery

    Tarnów

Other trials in Poland

About this study

Official title: Herniectomy vs. Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

The study aims at assessing the short and long-term effectiveness and patient perception of benefit with the use of a DIAM™ Spinal Stabilization System in the treatment of complex disc disease at a single level from L2 to L5.

Read the detailed description

This study is a multi-center, prospective, randomized, controlled trial. Patients will be randomized in 2 groups:

Investigational group: a single level herniectomy procedure, followed by placement of the DIAMTM Spinal Stabilization System; Control group: a single level herniectomy procedure; After surgery, patients will be followed for a 2 years period with required follow up visits at 6 weeks, 3 months, 6 months, 1 year, 2 years and 4 years (optional visit).

Conditions
Sciatica, Back Pain
Being tested
DIAM™ Spinal Stabilization System, Herniectomy
Medical subject headings
Sciatica, Back Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DIAM™ Spinal Stabilization SystemDevice

    The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.

  • HerniectomyProcedure or surgery

    Herniectomy is defined as the "removal of the extruded/protruded/sequestrated disc material". This is done by probing the annulus and disc space and removing all mobile disc fragments.

Study groups in NCT00749996
Study groupRoleWhat they receive
Investigational groupExperimentalSingle level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
Receives: Device: DIAM™ Spinal Stabilization System
Control groupActive comparatorSingle level herniectomy
Receives: Procedure: Herniectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 6-month of the Patient's Back-pain Score on a Visual Analogue Scale (VAS).

    The endpoint will be the difference between baseline and 6 months of the patient's back-pain score on a Visual Analogue Scale (VAS). A standardized visual analogue scale (0cm-10cm; with 0cm meaning 'no pain' and 10cm meaning 'worst possible pain') will be used. Large values of the VAS score represent large degree of pain. Large (negative) change in VAS score (6 months - baseline) represents large relief of pain. For treated subjects, all analyses except the safety analyses, Intent-To-Treat population will serve as the primary analysis dataset.

    Measured: 6 Months

Secondary outcomes (1)
  1. To Demonstrate a Statistically Significant Difference in the Reduction of Disability Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 12 Months of the Patient's Score on the Oswestry Disability Index (ODI).

    The endpoint will be the difference between baseline and 12 months of the patient's score on the Oswestry Disability Index (ODI).

    The ODI is a low back pain disability questionnaire used to measure a patient's permanent functional disability in a scale from 0 to 50 (when all the 10 sections are answered); large ODI scores indicate large disability.

    Measured: 12 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2008 (estimated)
  2. Study startNov 2006
  3. Primary completionApr 2013
  4. Study completionJun 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
165 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00749996
Sponsor's protocol ID
DIAM™ Study
Status last verified
Jan 2016
First submitted
9 Sep 2008
Last updated
28 Jan 2016
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing DIAM™ Spinal Stabilization System and Herniectomy in people with Sciatica and Back Pain, run by Medtronic Spinal and Biologics at 19 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 19 sites in Belgium, Germany, Switzerland, United Kingdom, Italy and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 May 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and 6-month of the Patient's Back-pain Score on a Visual Analogue Scale (VAS). (time frame: 6 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT00749996 | AzTrials